/PRNewswire/ Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid.
Innumerable cultural, social, and psychological forces shape the decisions we make. And our rationales for a decision are often tacked onto our actions after we have made our decision. That is, we make a decision first and then, consciously or unconsciously, we construct reasons why it was the correct one, reasons that fit the decision, our personal identity, or our desire to be seen as consistent or logical even if the original motive for the decision may have been different or even unknown to us.
We do this is as a way to avoid what is called post-decision dissonance. Studies have found that, after choosing, for example, a new job or which university to attend, people will rank the attributes of their chosen institution higher than they did before making their decision and no surprise rank the attributes of the loser lower. In addition, we make decisions that allow us to feel we are being consistent. So past decisions shape future decisions. For instance, perhaps you bought GMO-fr
A Black man s risk of getting prostate cancer is 75% higher than it is for a White man and the disease is twice as deadly but genetic risks for people of various racial and ethnic groups is coming into focus.
A new study focusing on COVID-19 immunity study that was recently published by the Centers for Disease Control and Prevention suggests that asymptomatic patients and those with mild COVID-19 cases will develop strong immune responses that can be traced through antibody tests.
This can be detected up to eight months after the infection. In addition, the study found that after eight months, more than half of the participants had neutralizing antibodies.
These responses will allow the immune system to fight the virus in the future, according to Boy Genius Report.
In a sense, the COVID-19 vaccines will deliver immunity that is at least as good as the protection acquired after the infection with the virus.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
The progression of cancer and autoimmune diseases are both characterised by intense inflammation and both diseases recruit immune cells to quell the escalating inflammation. In cancer, the recruitment of these cells, primarily regulatory (suppressor) T cells, attempt to resolve the ongoing inflammation with the result of turning down anticancer immunity. In autoimmune diseases, the constant stimulation of inflammation (immune reaction against the body’s own tissues) overwhelms the regulatory T cells. In both diseases other immune cells can also suppress immunity, with similar results as regulatory T cells. Furthermore, the biochemical pathways that regulate immune cell function are the same in both diseases.